Despite the well-documented association between gallstones and the metabolic syndrome 1,2 , the mechanistic links between these two disorders remain unknown. Here we show that mice solely with hepatic insulin resistance, created by liver-specific disruption of the insulin receptor (LIRKO mice) 3 are markedly predisposed toward cholesterol gallstone formation due to at least two distinct mechanisms. Disinhibition of the forkhead transcription factor FoxO1, increases expression of the biliary cholesterol transporters Abcg5 and Abcg8, resulting in an increase in biliary cholesterol secretion. Hepatic insulin resistance also decreases expression of the bile acid synthetic enzymes, particularly Cyp7b1, and produces partial resistance to the farnesoid X receptor, leading to a lithogenic bile salt profile. As a result, after twelve weeks on a lithogenic diet, all of the LIRKO mice develop gallstones. Thus, hepatic insulin resistance provides a crucial link between the metabolic syndrome and increased cholesterol gallstone susceptibility.
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Gallstones represent a major health problem in the US, affecting more than 20 million people 4 and resulting in at least $6 billion in healthcare costs annually 5 . There are several predisposing factors to cholesterol gallstones, but the association with obesity, first noted over 100 years ago 6 , is among the strongest. We now recognize this association as part of the more complex metabolic syndrome 1, 2 , which includes insulin resistance, central obesity, varying degrees of impaired glucose tolerance, hepatic steatosis and increased risk of cardiovascular disease. Insulin resistance plays a central part in the pathogenesis of the metabolic syndrome 7 , but how it is linked to gallstone formation has remained a mystery. The LIRKO mouse offers a unique model to study the effects of complete hepatic insulin resistance and its role in cholesterol gallstone formation. LIRKO mice were generated using the Cre-loxP system to specifically ablate the insulin receptor in hepatocytes 3 . Previous studies 3, 8 of the LIRKO mouse showed that hepatic insulin resistance produces many features of the metabolic syndrome, including increased hepatic glucose production, hyperglycemia, hyperinsulinemia and dyslipidemia. To determine whether LIRKO mice were also more susceptible to cholesterol gallstone formation, we challenged them and their littermate controls (Lox) with a lithogenic diet containing 0.5% cholic acid, 1% cholesterol and 15% dairy fat. After only 1 week on this diet, LIRKO gallbladders were filled with cholesterol monohydrate crystals, and 36% acquired gallstones, compared to 0% of the control mice ( Fig. 1) . After 12 weeks on the lithogenic diet, 100% of LIRKO mice developed gallstones, whereas 40% of controls still manifested normalappearing gallbladders and no visible stones (Fig. 1d) .
To identify the pathophysiological mechanisms by which insulin resistance increases gallstone susceptibility, we studied Lox and LIRKO mice on a normal chow diet. Real-time PCR revealed decreased expression of the major enzymes of the bile acid synthetic pathways Cyp7a1, Cyp8b1, Cyp7b1 and Cyp27a1 by 30-80% (Fig. 2a) . Consistent with this, bile acid synthesis, measured by steady-state fecal bile acid excretion, was decreased 40% (Fig. 2b) . In addition, LIRKO bile showed a marked decrease in the ratio of muricholates to cholate, making it more hydrophobic, and hence more lithogenic 9 , than bile from control mice (Fig. 2c,d ). The nuclear hormone receptor farnesoid-X-receptor (FXR) plays a key role in regulating the bile salt profile. FXR action is antilithogenic 10, 11 , and treatment of Lox mice with an FXR agonist produced a sixfold increase in the ratio of muricholates to cholate (Fig. 2e) , decreasing bile hydrophobicity and lithogenicity. LIRKO mice showed reduced levels of FXR mRNA and protein ( Supplementary Fig. 1 online) . Although FXR agonist treatment increased expression of the small heterodimer partner, Shp (encoded by Nr0b2), and decreased expression of Cyp7a1 in LIRKO mice as it did in controls, it did not decrease Cyp8b1 expression, improve the bile salt profile (Fig. 2e) or prevent gallstone formation in LIRKO mice fed the lithogenic diet ( Fig. 2e and Supplementary  Fig. 1 ). Therefore, LIRKO mice are resistant to some actions of FXR.
Biliary cholesterol secretion was increased fourfold in LIRKO mice (Fig. 3a) . This resulted in a marked increase in the propensity of LIRKO bile to form cholesterol gallstones. The relative lipid compositions of bile from control mice plotted in a zone in which only micelles would form at equilibrium on equilibrium phase diagrams, but bile from LIRKO mice plotted in zones in which liquid crystals or both liquid crystals and cholesterol monohydrate crystals in addition to micelles would form at equilibrium (Fig. 3b) . Consistent with this, the cholesterol saturation index of LIRKO bile was increased ( Fig. 3c and Supplementary Table 1 online). Gallbladder volume was increased threefold in LIRKO mice (Fig. 3d) , consistent with impaired motility and increased biliary cholesterol content 12 . Because fractional cholesterol absorption from the gut was similar in Lox and LIRKO mice (Fig. 3e) , the absolute amount of cholesterol absorbed from the gut in LIRKO mice should be increased because of their high levels of biliary cholesterol secretion. This was associated with a twofold increase in hepatic cholesterol (Fig. 3f) and decreased expression of sterol regulatory element-binding protein-2 and its targets 8 .
Biliary cholesterol secretion is regulated by the heterodimeric cholesterol transporters Abcg5 and Abcg8 (refs. 13,14) . LIRKO mice showed a two-to threefold increase in the expression of these proteins at the mRNA (Fig. 3g ) and protein levels (Fig. 3h) , accounting for the increased biliary cholesterol secretion observed in LIRKO mice. This increase in Abcg5 and Abcg8 was a direct effect of insulin resistance. Indeed, in rat hepatoma cells, insulin suppressed expression of Abcg5 and Abcg8 mRNA at subnanomolar concentrations in a doseresponsive manner that paralleled the suppression of the well described insulin target, phosphoenolpyruvate carboxykinase (Pck1; Fig. 4a ). Treatment with an FXR agonist had no effect on Abcg5 and Abcg8 ( Fig. 4b and Supplementary Fig. 1b ), but treatment with a liver-X-receptor (LXR) agonist increased expression of these genes and impaired the ability of insulin to suppress them (Fig. 4b) , consistent with the known ability of LXR to induce Abcg5 and Abcg8 expression in vitro and in vivo 15 .
In humans, the ABCG5 and ABCG8 genes are arranged head-tohead on chromosome 2, separated by 374 base pairs 16 . This region lacks a canonical LXR response element 16 and did not respond to an LXR agonist in a reporter assay (Fig. 4c) . Nonetheless, it responded to insulin in both the ABCG5 and ABCG8 orientations (Fig. 4c) . These data indicate the presence of an element in the intragenic region of the ABCG5 and ABCG8 genes that responds to insulin independently of LXR.
To better define this element, we studied the activity of a series of ABCG8 deletion constructs (Fig. 4d) . Insulin suppressed the fulllength construct by approximately 60%, whereas constructs lacking base pairs -32 to -162 were suppressed by only 20%, indicating at least one insulin-responsive element in this region (Fig. 4d) . Examination of this region revealed the sequence TGTTT, which is part of a well-characterized insulin response element that is present in Pck1, glucose-6-phosphatase (G6pc) and insulin-like growth factor-binding protein-1 (Igfbp1) 17 . This motif binds the winged helix-forkhead transcription factors, such as FoxO1, and can mediate the suppressive effect of insulin on these genes 17 .
Indeed, overexpression of a constitutively active form of FOXO1 (ref. 18) in rat hepatoma cells produced a fourfold increase in Abcg5 and Abcg8 expression and significantly blunted the ability of insulin to suppress these genes (Fig. 4e) . Similar effects were seen in Pck1, G6pc and Igfbp1 (Fig. 4e) , consistent with previous reports 17 insulin still retained some ability to suppress Abcg5 and Abcg8 expression in the presence of constitutively active FOXO1 suggests that insulin regulates these genes through both FOXO1-dependent and FOXO1-independent mechanisms. Finally, we examined transgenic mice overexpressing constitutively active human FOXO1 in liver under the promoter for a1-antitrypsin 18 . These mice showed several features of the metabolic syndrome, including hyperglycemia and hyperinsulinemia 18 . Abcg5 and Abcg8 expression was increased two-to threefold at the mRNA level, showing that FOXO1 activation is sufficient to drive expression of Abcg5 and Abcg8 in vivo, as it is in vitro (Fig. 4f) 18 . However, overexpression of activated FOXO1 also increased expression of the bile acid synthetic enzymes, Cyp7a1, Cyp7b1 and Cyp27a1 (Fig. 4g) , indicating that other insulin-dependent pathways are involved in the regulation of these enzymes, as evidenced by LIRKO mouse. Although FOXO1 clearly activates transcription of Abcg5 and Abcg8 expression in vitro and in vivo, whether this is mediated by direct or indirect mechanisms, such as coactivation of the endo-and xenobiotic receptors, CAR and PXR 19 , is not known. In either case, this seems to be a general mechanism by which insulin resistance promotes cholesterol gallstone formation, as increased expression of ABCG5 and ABCG8 is associated with increased gallstone formation in both humans 20 and mice 21 . Moreover, increased expression of Abcg5 and Abcg8 is observed in mice with diet-induced obesity (Supplementary Table 2 online), and increased biliary cholesterol secretion has been documented in mice with insulin deficiency 22 as well in as humans with the metabolic syndrome 23, 24 .
Insulin resistance also plays a part in gallstone formation through regulation of bile acid synthesis, but this is more complicated than regulation of cholesterol secretion. Cyp7a1 expression is increased in the insulin-deficient mouse 25 but decreased in the LIRKO mouse, the high-fat-fed obese mouse and the leptin-deficient ob/ob mouse, whereas Cyp8b1 expression is decreased in LIRKO mice but increased or unchanged in the other models (Supplementary Tables 2 and 3 online). In contrast, Cyp7b1 expression is consistently decreased by 40-70%, indicating that insulin is the major regulator of this gene in all of these models.
Cyp7b1 is the first committed enzyme in the acidic pathway of bile acid synthesis, which predominantly produces the muricholates 26 that are protective against cholesterol gallstone formation. Consistent with this, both LIRKO (this study) and insulin-deficient diabetic mice 22 show a marked decrease in the muricholate to cholate ratio and an increase in gallstone susceptibility. Furthermore, this effect of insulin involves downstream targets of FXR, as FXR agonist treatment of LIRKO mice does not improve the bile salt profile or reduce gallstone formation. In humans, the end product of the acidic pathway of bile acid synthesis is chenodeoxycholate. Chenodeoxycholate is more hydrophobic than the muricholates, but when it is given in pharmacological doses, it desaturates human gallbladder bile 27 . Therefore, it is not clear how a defect in the acidic pathway of bile acid synthesis would affect the lithogenicity of human bile, and studies in humans will be necessary to resolve this issue.
In summary, hepatic insulin resistance is sufficient to increase biliary cholesterol secretion and promote cholesterol gallstone formation-both features of the human metabolic syndrome 23, 24, 28 . These effects are due to disinhibition of FOXO1, which drives expression of Abcg5 and Abcg8, and to other factors, including resistance to FXR action. Therefore, hepatic insulin resistance links the hyperglycemia 3 , dyslipidemia 8 and gallstone formation of the metabolic syndrome. These findings also suggest that therapies that improve hepatic insulin resistance and decrease FOXO1 activity might prevent formation of cholesterol gallstones, in addition to having beneficial effects on glucose homeostasis.
METHODS
Mice and diets. We generated and genotyped LIRKO (Cre +/À Insr lox/lox ) mice, their littermate Lox controls (Cre À/À Insr lox/lox ) 3 and constitutively active FOXO1 transgenic mice 18 as previously described. LIRKO mice were on a mixed genetic background, including 129/Sv, C57BL/6, FVB and DBA, and inbred for more than ten generations. The FOXO1 transgenics were on an FVB background. We fed mice ad libitum with a standard chow diet (Mouse Diet 9F; PMI Nutrition International) or a lithogenic diet (0.5% cholic acid, 1% cholesterol and 15% dairy fat; Jackson Laboratories). Unless otherwise indicated, mice studied were male, chow-fed and killed in the nonfasted state.
We administered the FXR agonist, GW4064, at 100 mg/kg/d in PEG400/ Tween 80, 4:1 (vol/vol) or vehicle by gavage for 14 d as previously described 10 . Mice were fasted overnight and killed 2 h after the last dose of agonist. We killed mice that had been fed the lithogenic diet for 3 months after an overnight fast during which they had free access to water. We killed FOXO1 mice after fasting them for 24 h and then feeding them a high carbohydrate diet for 6 h. All animal studies followed the US National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees at the Joslin Diabetes Center or the University of Illinois at Chicago College of Medicine and the Jesse Brown Veterans Affairs Medical Center or the Harvard University Medical Area Standing Committee on Animals.
Biliary and hepatic lipid studies and cholesterol absorption. These studies are detailed in the Supplementary Methods online. We assessed bile acid synthesis by collecting feces for 72 h and measuring total bile acid outputs, as the synthesis of bile acids is equal to fecal excretion in the steady state. Hepatic bile was obtained by cannulating the common bile duct and gallbladder bile obtained by digitally expressing the contents of the gallbladder. We measured bile salt species by HPLC, comparing retention times with bile salt standards. Gallbladder bile obtained from mice treated with the FXR agonist showed some peaks attributable to the agonist itself, which represented less than 10% of the total bile acids. We determined biliary phospholipid concentrations by the inorganic phosphorus method; we measured biliary cholesterol by HPLC after extraction with hexane, and we measured total bile salts by a spectrophotometric assay based on 3a-hydroxysteroid dehydrogenase. Hepatic cholesterol was measured by gas chromatography or with an enzymatic assay (Wako Chemicals) and cholesterol absorption was measured by the fecal dual-isotope ratio method.
Real-time PCR analysis. We performed quantitative real-time PCR analysis of FOXO1 transgenic livers as described previously 18 and normalized expression to L32 ribosomal protein. In all other experiments, we isolated RNA (RNeasy, Qiagen) from mouse liver, prepared cDNA (RT for PCR, Clontech), performed quantitative real-time PCR in a fluorescent temperature cycler (Applied Biosystems) with either SYBR Green Master Mix (Roche) or the Taqman Universal master mix (Applied Biosystems; primers purchased through Assay on Demand) and normalized expression values to the amount of input RNA 29 . Primer sequences are given in Supplementary Table 4 online.
Western blot analysis. Preparation of liver and nuclear extract samples is detailed in the Supplementary Methods. Antibodies to ABCG5 (ref. 30 ) and ABCG8 (ref. 13) have been described previously. Antibodies to FXR were obtained commercially (Santa Cruz). We performed quantification with ImageJ software.
Gallbladder volumes and microscopy. After cholecystectomy, we manually expressed the gallbladder contents and weighed them. We calculated the volume by assuming a density of 1 g/ml. For prevalence studies, we placed gallbladders on a glass slide, incised them to release their contents, visualized them by direct and polarized-light microscopy and scored them for the presence of stones and cholesterol crystals.
Plasmids, transfections and luciferase assays. Luciferase constructs, encoding -1 to -374 base pairs of the human ABCG5-ABCG8 intragenic region have been previously described 16 . We made deletions by PCR amplification of the pABCG8-luc construct and ligation into PGL3 basic (Promega) using KpnI and BglII sites introduced by the PCR primers. For transfection experiments, we cultured cells in 24-well plates and transfected them at 50-80% confluence with 800 mg of the reporter plasmid and Lipofectamine 2000 (Invitrogen), per the manufacturer's instructions. For each plasmid, we used the same transfection mixture for all conditions. We measured firefly luciferase activity with the Dual Assay Luciferase kit (Promega) and normalized to activity in the absence of insulin or agonist. We performed at least three independent experiments, each in triplicate, with each plasmid. Data are presented as the means of three or more experiments.
Cell culture studies. We grew Fao rat hepatoma cells in RPMI supplemented with 10% serum, washed them three times in RPMI and cultured them in RPMI with or without insulin, 5 mM TO901317 (a synthetic LXR agonist, Sigma) or 50 nM GW4064. For adenoviral studies, we treated cells with equivalent amounts of control adenovirus (encoding LacZ) or adenovirus encoding constitutively active FOXO1, in which the three sites phosphorylated in response to insulin (Thr24, Ser256 and Ser319) were mutated to alanines 18 . After 48 h, cells were treated with insulin and assayed as above. Each experiment was performed in triplicate at least twice, and the results of a representative experiment are shown.
Statistical analyses. We calculated statistical significance by an unpaired Student's t-test. All data are expressed as the means ± s.e.m.
